Top-News

Novelos Therapeutics News

Aktie
WKN:  A1H9DF ISIN:  US67000M2098
Keine aktuellen Kursdaten verfügbar
Handeln Depot/Watchlist
Dieses Wertpapier ist nicht mehr handelbar.
Aktienanzahl *
57,40 Mio.
Marktkapitalisierung *
-
Streubesitz
-
Index-Zugehörigkeit
-
IR-Website
zur Website
*Stand: 25.05.2013

Novelos Therapeutics News

16.05.13 - PR Newswire
Novelos Therapeutics Provides Product Pipeline Update
Novelos Therapeutics Provides Product Pipeline Update To Begin I-124-CLR1404 (LIGHT) Phase 2 Imaging Trial in Brain Cancer in Early 2014 Evaluating I-131-CLR1404 (HOT) ...
21.02.13 - PR Newswire
Novelos Therapeutics Closes $5.5 Million Public Offering
Novelos Therapeutics Closes $5.5 Million Public Offering PR Newswire
13.02.13 - PR Newswire
Novelos Therapeutics Prices $5.5 Million Public Offering
Novelos Therapeutics Prices $5.5 Million Public Offering PR Newswire
04.02.13 - PR Newswire
Novelos Therapeutics To Present At The 15th Annual BIO CEO & Investor Conference On February 11
Novelos Therapeutics To Present At The 15th Annual BIO CEO & Investor Conference On February 11 PR Newswire
31.01.13 - PR Newswire
Novelos Therapeutics Presents Diapeutic Technology Platform At EMIT: Targeted Radiotherapy International Conference
Novelos Therapeutics Presents Diapeutic Technology Platform At EMIT: Targeted Radiotherapy International Conference Oral Presentation Highlights Cancer-​Targeted PET ...
27.11.12 - PR Newswire
Novelos Therapeutics To Present At The Benchmark 2012 Micro Cap Discovery Investor Conference On November 29
Novelos Therapeutics To Present At The Benchmark 2012 Micro Cap Discovery Investor Conference On November 29 PR Newswire
25.10.12 - PR Newswire
Novelos Therapeutics Announces Enrollment of First Patient in Solid Tumor Imaging Trial with I-124-CLR1404 (LIGHT) Cancer-targeted PET Imaging Agent at UW Carbone Cancer Center
Novelos Therapeutics Announces Enrollment of First Patient in Solid Tumor Imaging Trial with I-124-CLR1404 (LIGHT) Cancer-​targeted PET Imaging Agent at UW Carbone Cancer ...
03.10.12 - PR Newswire
Magnetar Financial LLC - Form 8.3:Magnetar Financial (UK) LLP - Glencore Intl Plc
Magnetar Financial LLC - Form 8.3:Magnetar Financial (UK) LLP - Glencore Intl Plc PR Newswire
03.10.12 - PR Newswire
WestJet reports record September load factor
WestJet reports record September load factor PR Newswire
03.10.12 - PR Newswire
Joint Study From AOL And BBDO Turns Traditional View of Mobile Space on its Head
Joint Study From AOL And BBDO Turns Traditional View of Mobile Space on its Head Goes Beneath The Mobile Surface To Uncover New Insights For Marketers, Agencies And ...
03.10.12 - PR Newswire
BNY Mellon to Host Third-Quarter 2012 Earnings Conference Call on Wednesday, October 17
BNY Mellon to Host Third-​Quarter 2012 Earnings Conference Call on Wednesday, October 17 PR Newswire
03.10.12 - PR Newswire
Voip-Pal.Com Inc. Prepares to Launch Account Management Software for Its PointsPhone Mobile™ Apps
Voip-Pal.Com Inc. Prepares to Launch Account Management Software for Its PointsPhone Mobile™ Apps PR Newswire
03.10.12 - PR Newswire
NFL Pro Bowler E.J. Henderson Supports Amarantus Biosciences #C4CT Concussion Program
NFL Pro Bowler E.J. Henderson Supports Amarantus Biosciences #C4CT Concussion Program PR Newswire
03.10.12 - PR Newswire
EMC and NCSA Offer Free Online Identity Risk Calculator
EMC and NCSA Offer Free Online Identity Risk Calculator Initial Results from Online Identity Risk Calculator Shows Risk Exposure to Internet-​borne Threats Highest Among Young ...
03.10.12 - PR Newswire
Novelos Therapeutics and Academic Collaborators Present Diapeutic Technology Platform at Imaging in 2020 Conference
Novelos Therapeutics and Academic Collaborators Present Diapeutic Technology Platform at Imaging in 2020 Conference Cancer-​Targeted PET Imaging, Therapeutic and Optical ...
02.10.12 - PR Newswire
Novelos Therapeutics to Present at 11th Annual Bio Investor Forum on October 10
Novelos Therapeutics to Present at 11th Annual Bio Investor Forum on October 10 PR Newswire
11.09.12 - PR Newswire
Novelos Therapeutics Successfully Completes Second Cohort In Phase 1b Solid Tumor Trial With I-131-CLR1404 (HOT) Cancer-Targeted Molecular Radiotherapeutic
Novelos Therapeutics Successfully Completes Second Cohort In Phase 1b Solid Tumor Trial With I-131-CLR1404 (HOT) Cancer-​Targeted Molecular Radiotherapeutic Additional ...
07.09.12 - PR Newswire
Novelos Therapeutics And Academic Collaborators Present Three Posters At 2012 World Molecular Imaging Congress
Novelos Therapeutics And Academic Collaborators Present Three Posters At 2012 World Molecular Imaging Congress Cancer-​Targeted Therapeutic I-131-CLR1404 (HOT) and ...
04.09.12 - PR Newswire
Novelos Therapeutics to Present at Rodman & Renshaw 14th Annual Healthcare Conference on September 11
Novelos Therapeutics to Present at Rodman & Renshaw 14th Annual Healthcare Conference on September 11 PR Newswire
28.08.12 - PR Newswire
Novelos Therapeutics Developing CLR1502 (GLOW2) Cancer-Targeted Optical Imaging Agent For Intraoperative Tumor Margin Illumination
Novelos Therapeutics Developing CLR1502 (GLOW2) Cancer-​Targeted Optical Imaging Agent For Intraoperative Tumor Margin Illumination Expects to File IND in Second Half of ...

Newssuche

Videos

newspaper
17.05.24 +14,15%
Technical Trading: Gold Long-​Chance
Gold Long Typ: Turbo Open End WKN: VD1G7Y Hebel: 10 Laufzeit: OpenEnd Einstieg: Market ... Mehr »